目的探讨麝香保心丸联合阿托伐他汀治疗急性冠脉综合征(ACS)患者的疗效及对血脂、血清基质金属蛋白酶8(MMP-8)和基质金属蛋白酶组织抑制因子1(TIMP-1)的影响。方法160例ACS患者随机分为观察组(n=80)和对照组(n=80)。对照组给予阿托伐他...目的探讨麝香保心丸联合阿托伐他汀治疗急性冠脉综合征(ACS)患者的疗效及对血脂、血清基质金属蛋白酶8(MMP-8)和基质金属蛋白酶组织抑制因子1(TIMP-1)的影响。方法160例ACS患者随机分为观察组(n=80)和对照组(n=80)。对照组给予阿托伐他汀治疗,观察组在对照组基础上给予麝香保心丸治疗。比较两组冠脉介入疗效,总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)及高密度脂蛋白胆固醇(HDL-C)等血脂指标水平,MMP-8、TIMP-1、C反应蛋白(CRP)和白细胞介素6(IL-6)等炎症因子水平,左心室收缩末期容积(LVESV)、左心室舒张末期容积(LVEDV)、左心室舒张末期容积指数(LVEDVI)及左心室射血分数(LVEF)等心功能指标水平,以及30 d主要心血管不良事件(MACE)发生情况。结果两组冠脉介入治疗总有效率比较,差异无统计学意义(χ^(2)=1.56,P>0.05);治疗后,观察组TC、TG、LDL-C水平均明显低于对照组,HDL-C水平明显高于对照组(t分别=2.30、2.03、2.57、-3.64,P均<0.05),观察组血脂达标率为43.33%,明显高于对照组血脂达标率25.00%(χ^(2)=4.48,P<0.05);治疗后,观察组MMP-8、CRP、IL-6水平及LVESV、LVEDV、LVEDVI均明显低于对照组,TIMP-1水平、LVEF明显高于对照组(t分别=2.29、2.19、8.55、2.17、2.29、2.37、-2.97、-2.40,P均<0.05);两组30 d MACE发生率比较,差异无统计学意义(χ^(2)=0.12,P>0.05)。结论麝香保心丸联合阿托伐他汀治疗ACS患者可有效改善患者血脂、心功能及降低炎症水平,利于稳定斑块。展开更多
Objective To study the clinical role of the variation of serum matrix metalloproteinase-8 (MMP-8) concentration in patients with acute coronary syndrome (ACS). Methods ELISA method was adopted to detect serum MMP-8 co...Objective To study the clinical role of the variation of serum matrix metalloproteinase-8 (MMP-8) concentration in patients with acute coronary syndrome (ACS). Methods ELISA method was adopted to detect serum MMP-8 concentration and to observe concentration’s differences and features among 80 selected ACS cases (43 acute myocardial infarction and 37 unstable angina pectoris), 43 stable angina pectoris (SAP) cases and 37 control cases. And meanwhile the atherosclerosis risk factors of each case, such as age, sex, hypertension, body mass index, smoking, family history, diabetes, and hyperlipidemia were collected and analyzed as a whole. Results First, serum MMP-8 concentration reached the highest point in ACS, and there was significant difference between SAP and control groups (P<0.01). Second, serum MMP-8 in AMI was much higher than that in UAP with significant difference (P<0.01). There was no difference between UAP and SAP groups (P>0.05). Third, Logistic regression analysis revealed that serum MMP-8 concentration might be the indicator of ACS (B=4.493, P=0.000), particularly, that of AMI (B=9.961, P=0.000). Fourth, linear correlation and linear regression analysis found that only neutrophil was likely to influence serum MMP-8 concentration (r=0.274, P=0.001). Fifth, in the diagnosis of ACS, the area under ROC curve of MMP-8 was 0.785, the sensitivity and specificity were 68.6% and 76.5%, respectively. Conclusion ① Serum MMP-8 concentration has close relationship with the occurrence of ACS, particularly with AMI; ② Serum MMP-8 concentration may be one of the predicting indicators of ACS and particularly of AMI; ③ Neutrophil may be correlated with serum MMP-8 concentration; ④ MMP-8 is of somewhat valuable in diagnosing ACS.展开更多
文摘目的探讨麝香保心丸联合阿托伐他汀治疗急性冠脉综合征(ACS)患者的疗效及对血脂、血清基质金属蛋白酶8(MMP-8)和基质金属蛋白酶组织抑制因子1(TIMP-1)的影响。方法160例ACS患者随机分为观察组(n=80)和对照组(n=80)。对照组给予阿托伐他汀治疗,观察组在对照组基础上给予麝香保心丸治疗。比较两组冠脉介入疗效,总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)及高密度脂蛋白胆固醇(HDL-C)等血脂指标水平,MMP-8、TIMP-1、C反应蛋白(CRP)和白细胞介素6(IL-6)等炎症因子水平,左心室收缩末期容积(LVESV)、左心室舒张末期容积(LVEDV)、左心室舒张末期容积指数(LVEDVI)及左心室射血分数(LVEF)等心功能指标水平,以及30 d主要心血管不良事件(MACE)发生情况。结果两组冠脉介入治疗总有效率比较,差异无统计学意义(χ^(2)=1.56,P>0.05);治疗后,观察组TC、TG、LDL-C水平均明显低于对照组,HDL-C水平明显高于对照组(t分别=2.30、2.03、2.57、-3.64,P均<0.05),观察组血脂达标率为43.33%,明显高于对照组血脂达标率25.00%(χ^(2)=4.48,P<0.05);治疗后,观察组MMP-8、CRP、IL-6水平及LVESV、LVEDV、LVEDVI均明显低于对照组,TIMP-1水平、LVEF明显高于对照组(t分别=2.29、2.19、8.55、2.17、2.29、2.37、-2.97、-2.40,P均<0.05);两组30 d MACE发生率比较,差异无统计学意义(χ^(2)=0.12,P>0.05)。结论麝香保心丸联合阿托伐他汀治疗ACS患者可有效改善患者血脂、心功能及降低炎症水平,利于稳定斑块。
文摘Objective To study the clinical role of the variation of serum matrix metalloproteinase-8 (MMP-8) concentration in patients with acute coronary syndrome (ACS). Methods ELISA method was adopted to detect serum MMP-8 concentration and to observe concentration’s differences and features among 80 selected ACS cases (43 acute myocardial infarction and 37 unstable angina pectoris), 43 stable angina pectoris (SAP) cases and 37 control cases. And meanwhile the atherosclerosis risk factors of each case, such as age, sex, hypertension, body mass index, smoking, family history, diabetes, and hyperlipidemia were collected and analyzed as a whole. Results First, serum MMP-8 concentration reached the highest point in ACS, and there was significant difference between SAP and control groups (P<0.01). Second, serum MMP-8 in AMI was much higher than that in UAP with significant difference (P<0.01). There was no difference between UAP and SAP groups (P>0.05). Third, Logistic regression analysis revealed that serum MMP-8 concentration might be the indicator of ACS (B=4.493, P=0.000), particularly, that of AMI (B=9.961, P=0.000). Fourth, linear correlation and linear regression analysis found that only neutrophil was likely to influence serum MMP-8 concentration (r=0.274, P=0.001). Fifth, in the diagnosis of ACS, the area under ROC curve of MMP-8 was 0.785, the sensitivity and specificity were 68.6% and 76.5%, respectively. Conclusion ① Serum MMP-8 concentration has close relationship with the occurrence of ACS, particularly with AMI; ② Serum MMP-8 concentration may be one of the predicting indicators of ACS and particularly of AMI; ③ Neutrophil may be correlated with serum MMP-8 concentration; ④ MMP-8 is of somewhat valuable in diagnosing ACS.
